CBT 101 - CBT Pharmaceuticals

Drug Profile

CBT 101 - CBT Pharmaceuticals

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator CBT Pharmaceuticals
  • Developer Beijing Pearl Biotechnology
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Sep 2016 CBT 101 licensed to Beijing Pearl Biotechnology in China (CBT Pharmaceuticals pipeline, August 2016)
  • 31 Aug 2016 Phase-I clinical trials in Cancer in China (PO) before August 2016 (CBT Pharmaceuticals pipeline, August 2016)
  • 31 Aug 2016 CBT Pharmaceuticals plans a phase I trial for Cancer in USA (CBT Pharmaceuticals pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top